fuzzy, I wouldn't count on ZCC for the following reasons;

1. no trial is beyond phase 2
2. warrants, with one exception, are all dated 2028
3. Don is the CEO of ZCC.

On the other hand the ZCC management team (Dr Lakhotia) has been able to establish relationships with the NCI and numerous BPs with numerous partner drugs, so, perhaps the odds are better than at RVX which has achieved nothing since the end of BoM.

We've all witnessed the dramatic increase in "withhold" votes for Don at the last GM. The number, above 5%, is actually a huge expression of discontent. If Don's reputation in the larger investment community is as low as it is among shareholders like me I would imagine finding investors who have done their due diligence to be a very difficult challange. Don has given us every reason not to trust him and based on the performance, over the last 4 years at least, why would someone about to invest large sums of money have any trust in Don?

If I was given the job of rebuilding the RVX brand I would focus 99% of the brand positioning on the RVX scientific successes (and their are many), the burgeoning science of epigenetic medicine, 1% on the RVX management teams strengths (whatever that may be), and I would eliminate Don entirely from the brand. Most of the content in RVX updates are scientific. I would give this job the Dr Kulikowiski and Dr Sweeney. The business side would be presented by the CFO. Don would not be present. This brand must build trust in the science and business competence. I would also hire a team of professional writers to produce a continuous flow in scientific insights about RVX and the developing science of epigenetics. I would also empasize that this is a Canadian based multinational company.

A brand positioning and communication strategy is needed... but so is a financial strategy...go figure...duh      :)

Now for a bit of Hump Day levity. Does anyone have the scoop on, or evidence of, which golf courses in Morocco, Dubai or the UAE, etc where Don and his managemnet team are scoring deals at?

I remain long on the science.

GLTA, we'll need it.

Toinv